PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Prior to the 2023 season, we shared with you some fascinating news, which was that a losing team was all but guaranteed to find themselves getting into the playoffs the next season. Nothing is ever ...

One participant’s biopsy was not collected at day 28 due to pseudoaneurysm in connection with the biopsy procedure. One participant’s sample showed a splicing index outside the pre-specified ...

J Gastroenterol Hepatol. 2009;24(4):509-519. One of the most important issues may be the introduction of rapid staining performed by a cytopathologist or cytotechnician during the procedure ...

– The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...